RxDoctor Payments Data

Stuart Bursten, MD

Internal Medicine · Vista, CANPI 1164494696

Payments from drug & device makers

$1,055in general payments, 2019–2025

Across 48 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$178
  • Otsuka America Pharmaceutical, Inc.$119
  • AstraZeneca$95
  • GSK$95
  • Lilly USA, LLC$81
  • Exact Sciences$71
  • plus $417 from 15 others

What the payments were for

  • Food & beverage$1,055100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,055 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$98,680
Medicare patients
418
Services billed
1,426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide46$42,989
MounjaroTirzepatide24$25,092
JardianceEmpagliflozin23$23,012
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$22,714
OzempicSemaglutide15$15,425
EliquisApixaban19$13,758
JanuviaSitagliptin Phosphate15$8,584
Duloxetine Hcl45$1,943
Celecoxib64$1,259
Nifedipine ErNifedipine23$1,143
Valsartan45$808
Levothyroxine Sodium63$769
Atorvastatin Calcium73$657
Rosuvastatin Calcium56$657
ProgesteroneProgesterone, Micronized16$611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$81$68,08170 claims
GSKTrelegy Ellipta$95$22,71431 claims
Novo NordiskOzempic$17$15,42515 claims
PfizerEliquis$52$13,75819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →